Galapagos Genomics said this week changes to its board of directors.
According to the company, Ferdinand Verdonck has joined as independent director, and Harrold van Barlingen has joined as dependent director.
Verdonck was most recently managing director of Almanij (now merged with KBC). He currently is on the board of several companies, including Banco Urquijo and Dictaphone. He holds a law degree from the KU Leuven and degrees in economics from KU Leuven and the University of Chicago, said Galapagos.
Van Barlingen heads life sciences investments activities at the private equity firm AlpInvest Partners, said Galapagos. Prior to this, he was a management and strategy consultant at the Boston Consulting Group. He holds an MSc in medical biology and a PhD in cardiovascular diseases from the University of Utrecht.
Steven Quay, chairman, president, and CEO of Nastech Pharmaceuticals, has been named a finalist by Ernst & Young for the financial services firm's Entrepreneur of the Year 2005 Awards in the Pacific Northwest.
According to Nastech, Quay was selected from 40 nominations in the Pacific Northwest by a panel of independent judges comprised of area leaders from business, academic, and civic organizations. Winners of the awards will be announced on June 23.
Roger Wiegand has become director of the infectious disease initiative at the Broad Institute, RNAi News' sister publication GenomeWeb News has learned.
Prior to joining the Broad, he was chief scientific officer of Cantata Laboratories in Cambridge, Mass.
Sangamo BioSciences said this week that it has appointed Steven Mento to its board of directors.
Mento is currently the president and CEO of Idun Pharmaceuticals. He holds a BA in microbiology from Rutgers College, as well as an MS and PhD from Rutgers University.